Content
Frontiers of Medicine >> 2022, Volume 16, Issue 3 doi: 10.1007/s11684-021-0869-y
Rapamycin enhances the anti-tumor activity of cabozantinib in cMet inhibitor-resistant hepatocellular carcinoma
Abstract
Keywords
hepatocellular carcinoma ; cabozantinib ; primary resistance ; rapamycin
Content